Tiziana Life Sciences (TILS)

 

Latest News

Broker Forecast - Beaufort Securities issues a broker note on Tiziana Life Sciences Plc Ord 3p

Beaufort Securities today reaffirms its speculative buy investment rating on Tiziana Life Sciences Plc Ord 3p (LON:TILS) ...

TILS confirms Phase II clinical trial protocol for Milciclib

Tiziana Life Sciences has announced the approval in Israel of a phase II clinical trial protocol for testing milciclib, a novel ...

Announces Approval of a Phase II Clinical Trial

RNS Number: 0864D Tiziana Life Sciences PLC 24 April 2017 Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with Hepatocellular Carcinoma In mouse models of HCC, oral administration with milciclib effectively suppressed tumour growth London, 24 A...

Announces Publication of Milciclib Clinical Trial

RNS Number: 9222C Tiziana Life Sciences PLC 21 April 2017 Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences Announces Publication of Peer-Reviewed Paper from Positive Clinical Trial of Milciclib in Patients with Refractory Solid Tumours Encouraging data from phase I study published in Cancer Chemotherapy and Pharmacology L...

All News

DateHeadlineSource
24-04-17Broker Forecast - Beaufort Securities issues a broker note on Tiziana Life Sciences Plc Ord 3pStockMarketWire
24-04-17TILS confirms Phase II clinical trial protocol for Milciclib StockMarketWire
24-04-17Announces Approval of a Phase II Clinical TrialRNS
21-04-17Announces Publication of Milciclib Clinical TrialRNS
24-03-17Tiziana Life Sciences notes exercise of warrantsStockMarketWire
24-03-17Exercise of Warrants & Issue of EquityRNS
14-03-17Arun Sanyal appointed to Scientific Advisory BoardRNS
16-01-17Warrant Expiry - ReminderRNS
03-01-17Tiziana Life Sciences in-licences NI-1201StockMarketWire
03-01-17Tiziana Life Sciences in-licenses NI-1201RNS
16-11-16Tiziana announces new data with ForalumabStockMarketWire
16-11-16New Data with ForalumabRNS
07-11-16Tiziana CFO awarded options StockMarketWire
07-11-16Grant of optionsRNS
29-09-16Half-year ReportRNS
15-09-16Confirmation of Capital ReductionRNS
18-08-16Change of Registered OfficeRNS
18-07-16Tiziana acquires a unique bio-repositoryStockMarketWire
18-07-16Tiziana acquires a unique bio-repositoryRNS
30-06-16Result of AGMRNS
29-06-16Issue of EquityRNS
10-06-16Grant of options and realisation bonusRNS
07-06-16Tiziana Life Sciences widens FY pretax lossStockMarketWire
07-06-16Final ResultsRNS
01-06-16Partnership with Cardiff Researchers Wins AwardRNS
19-05-16Journal review of anti - CD3 monoclonal antibodiesRNS
04-05-16Appointment of Dr. Robert EvansRNS
28-04-16Exercise of Warrants & Issue of EquityRNS
04-04-16Tiziana Life Sciences appoints CFOStockMarketWire
04-04-16Chief Financial Officer AppointedRNS
15-03-16Co-Founder and NED Prof Chris McGuigan Passes AwayRNS
16-02-16Second Price Monitoring ExtnRNS
16-02-16Price Monitoring ExtensionRNS
13-01-16Tiziana Life Sciences raises GBP0.7m in CLN issueStockMarketWire
13-01-16Fund raisingRNS
11-01-16Development plans for foralumab & SAB appointmentsRNS
08-01-16Update on Tiziana's Bcl-3 inhibitorRNS
31-12-15How AIM smashed blue chips in 2015Interactive Investor
09-12-15Tiziana appoints COO StockMarketWire
09-12-15Appoints James F. Tripp as Chief Operating OfficerRNS

RSS feeds

  • Editorial news feed for LSE:TILS Editorial
  • Regulatory news feed for LSE:TILS Regulatory